BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $19.50 Average PT from Brokerages

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have received a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $19.50.

Several equities analysts recently commented on the company. Cantor Fitzgerald boosted their target price on BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 15th. Zacks Research lowered BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Citizens Jmp decreased their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating on the stock in a research report on Wednesday, November 5th. TD Cowen initiated coverage on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 15th. They set a “buy” rating and a $30.00 target price for the company. Finally, Needham & Company LLC decreased their price target on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, November 4th.

BioCryst Pharmaceuticals Trading Down 4.2%

Shares of NASDAQ:BCRX opened at $6.42 on Monday. The company has a 50 day moving average of $7.26 and a 200 day moving average of $7.54. The stock has a market cap of $1.35 billion, a P/E ratio of -128.40, a P/E/G ratio of 0.45 and a beta of 0.83. BioCryst Pharmaceuticals has a 12 month low of $6.00 and a 12 month high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, November 3rd. The biotechnology company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.01). The firm had revenue of $159.40 million during the quarter, compared to the consensus estimate of $162.91 million. BioCryst Pharmaceuticals had a negative net margin of 1.46% and a negative return on equity of 4.24%. The firm’s revenue for the quarter was up 36.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.07) earnings per share. On average, equities analysts forecast that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

Insider Buying and Selling

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 91,004 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $7.10, for a total transaction of $646,128.40. Following the sale, the insider owned 416,152 shares in the company, valued at $2,954,679.20. This trade represents a 17.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 183,453 shares of company stock valued at $1,330,965 over the last quarter. 5.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several institutional investors have recently modified their holdings of BCRX. Vanguard Group Inc. lifted its position in BioCryst Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock worth $173,732,000 after buying an additional 482,494 shares during the last quarter. Deerfield Management Company L.P. grew its position in BioCryst Pharmaceuticals by 159.4% during the third quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock valued at $92,363,000 after acquiring an additional 7,477,000 shares during the last quarter. State Street Corp raised its stake in shares of BioCryst Pharmaceuticals by 8.9% during the second quarter. State Street Corp now owns 8,505,392 shares of the biotechnology company’s stock worth $76,208,000 after acquiring an additional 691,988 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of BioCryst Pharmaceuticals by 22.1% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 5,225,986 shares of the biotechnology company’s stock worth $39,665,000 after acquiring an additional 947,431 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of BioCryst Pharmaceuticals by 1.9% in the 2nd quarter. Geode Capital Management LLC now owns 5,054,610 shares of the biotechnology company’s stock valued at $45,296,000 after purchasing an additional 93,973 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.